- Strengthened BiOrigin Entrepreneur-in-residence Advisory Unit with seasoned CEOs
- REPAIR Impact investments now total USD 48 million in eight companies since its inception
- Significant progress with portfolio companies
- Successful Seed Summit at Novo Holdings headquarters
Copenhagen, Denmark, Novo Seeds, the early stage investment and company creation team of Novo Holdings, today publishes its review of 2019 – a year of significant progress and growth. For more information, please see the Novo Seeds January 2020 Newsletter.
Along with the significant advances made by Novo Seeds portfolio companies, 2019 saw the team make five new investments. These included four new financings by the REPAIR Impact Fund bringing the total committed to date to USD 48 million. Novo Seeds also co-led the EUR 20 million Series A funding in STipe Therapeutics, a company that we created and incubated with the founder team to exploit the stimulator of interferon genes (STING) pathway. 2019 also saw Novo Seeds strengthen its BiOrigin Entrepreneur-in-residence Advisory Unit with the appointment of seasoned CEOs as the team bolsters its activities in identifying, building and investing in exceptional life sciences start-ups.